Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan Miller

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinomaMei-Kim Ang, Mihir R Patel, Xiao-Ying Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
Breast Cancer Research : BCR|February 8, 2018
Frequency of breast cancer subtypes among African American women in the AMBER consortiumEmma H Allott, Joseph Geradts, Stephanie M Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Science Translational Medicine|July 8, 2026
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastomaArifa Nayab, Nouman Mughal, Meher Angez, et al.
Archives of Pathology & Laboratory Medicine|May 16, 2012
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsetsJuneko E Grilley-Olson, D Neil Hayes, Dominic T Moore, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
Acta Neuropathologica Communications|June 28, 2025
Identifying and exploiting combinatorial synthetic lethality by characterizing adaptive kinome rewiring of EGFRvIII-driven glioblastomaBenjamin Lin, Abigail K Shelton, Erin Smithberger, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2011
High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinomaMei-Kim Ang, Mihir R Patel, Xiao-Ying Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2015
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in MelanomaCraig C Carson, Stergios J Moschos, Sharon N Edmiston, et al.
Breast Cancer Research : BCR|February 8, 2018
Frequency of breast cancer subtypes among African American women in the AMBER consortiumEmma H Allott, Joseph Geradts, Stephanie M Cohen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.
Cancer Cell|February 5, 2010
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1Roel G W Verhaak, Katherine A Hoadley, Elizabeth Purdom, et al.
Science Translational Medicine|May 26, 2017
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activationDavid P Kodack, Vasileios Askoxylakis, Gino B Ferraro, et al.
Science Translational Medicine|July 8, 2026
EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastomaArifa Nayab, Nouman Mughal, Meher Angez, et al.
Archives of Pathology & Laboratory Medicine|May 16, 2012
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsetsJuneko E Grilley-Olson, D Neil Hayes, Dominic T Moore, et al.
Pageof 23